Banco Bilbao Vizcaya Argentaria S.A. Buys 4,204 Shares of Stryker Corporation $SYK

Banco Bilbao Vizcaya Argentaria S.A. raised its position in Stryker Corporation (NYSE:SYK) by 6.8% during the second quarter, Holdings Channel reports. The institutional investor owned 65,670 shares of the medical technology company’s stock after buying an additional 4,204 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Stryker were worth $25,968,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. bought a new stake in Stryker during the 2nd quarter worth about $26,000. Sachetta LLC grew its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares during the period. Ridgewood Investments LLC raised its stake in shares of Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after buying an additional 30 shares during the last quarter. Ransom Advisory Ltd acquired a new position in Stryker in the first quarter valued at approximately $37,000. Finally, Solstein Capital LLC bought a new position in Stryker in the second quarter valued at approximately $43,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This trade represents a 9.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 520,500 shares of company stock valued at $184,803,065 over the last 90 days. Corporate insiders own 5.20% of the company’s stock.

Stryker Trading Up 1.5%

Shares of Stryker stock opened at $372.93 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The business has a fifty day simple moving average of $372.55 and a two-hundred day simple moving average of $381.18. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a market capitalization of $142.62 billion, a price-to-earnings ratio of 49.40, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the previous year, the company posted $2.87 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of recent analyst reports. Rothschild Redb upgraded Stryker to a “hold” rating in a report on Thursday, September 18th. Wells Fargo & Company upped their price target on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. BTIG Research lifted their price objective on shares of Stryker from $408.00 to $410.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Truist Financial restated a “hold” rating and set a $392.00 price objective (down previously from $407.00) on shares of Stryker in a report on Monday, November 3rd. Finally, Evercore ISI cut their target price on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Thirteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $433.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.